PRQRProQR Therapeutics BV
About ProQR Therapeutics BV
ProQR Therapeutics (NASDAQ:PRQR) is a biotech firm focused on the development of transformative RNA therapies for severe genetic rare diseases. Based out of the Netherlands, ProQR is dedicated to pioneering new ways to treat diseases that have limited or no treatment options. The company's research primarily centers on targeting disorders in the liver and central nervous system, as well as certain eye diseases. Among its notable projects are therapies aimed at addressing conditions like cystic fibrosis and dystrophic epidermolysis bullosa. ProQR’s objective is to leverage its proprietary RNA repair platform technologies to create medicines that can profoundly improve the lives of patients suffering from these debilitating diseases.
What is PRQR known for?
Snapshot
Public US
Ownership
2012
Year founded
157
Employees
Leiden, Netherlands
Head office
1 of 5
US Rank
Unknown
Sector
N/A
Sector rank
Loading Map...
Operations
All Locations
Kingdom of the Netherlands
Products and/or services of ProQR Therapeutics BV
- Axiomer Editing Oligonucleotides technology, a next-generation RNA editing platform aimed at making precise, single nucleotide changes to RNA to correct genetic diseases.
- Sepofarsen, a first-in-class RNA therapy for Leber’s Congenital Amaurosis 10 (LCA10), aiming to restore vision in individuals with this inherited retinal disease.
- QR-421a, an investigational RNA-based therapy targeting Usher syndrome and non-syndromic retinitis pigmentosa, focusing on mutations in the USH2A gene.
- QR-1123, a therapy aimed at treating autosomal dominant retinitis pigmentosa caused by the P23H mutation in the RHO gene, intended to preserve vision.
- QR-504a, a therapy targeting Fuchs Endothelial Corneal Dystrophy (FECD), designed to address the trinucleotide repeat expansion in the TCF4 gene associated with the disease.
- Eluforsen, developed for the treatment of cystic fibrosis, targets the F508del mutation in the CFTR gene to improve lung function and respiratory symptoms.
ProQR Therapeutics BV executive team
- Mr. Daniel Anton de BoerFounder, CEO & Member of Management Board
- Dr. Gerard Platenburg Ph.D.Co-Founder, Chief Scientific Officer & Member of Management Board
- Dr. Domenico Valerio Ph.D.Founder & Independent Member of Supervisory Board
- Mr. Dennis HomChief Financial Officer
- Ms. Sheila SponseleeChief People & Operations Officer
- Ms. Sarah Cue KielyVice President of Investor Relations & Corporate Communications
- Dr. Cristina Lopez Lopez M.D., Ph.D.Chief Medical Officer
- Ms. Sandra van der KolkJunior Financial Controller